Clareon PanOptix Pro vs. Clareon PanOptix - Study B

Contralateral Study of Clareon PanOptix Pro vs. Clareon PanOptix

The purpose of this study is to evaluate the safety and effectiveness of Clareon™ PanOptix™ Pro Trifocal Intraocular Lens (IOL) compared to Clareon™ PanOptix™ Trifocal IOL.

Subjects will attend 9 scheduled study visits for a total individual duration of participation of approximately 6 months. The primary endpoint will be assessed at the Month 2 follow-up visit. Both eyes of a subject must qualify for enrollment into this study.

Key Inclusion Criteria:

• Understand and sign an ethics committee-approved informed consent form;
• Willing and able to attend all scheduled study visits as required by the protocol;
• Planned cataract surgery (both eyes);
• Preoperative corneal astigmatism less that 1.00 diopter in each eye.
• Other protocol-defined inclusion criteria may apply.

Key Exclusion Criteria:

• Women of childbearing potential if currently pregnant, intend to become pregnant during the study, or are breastfeeding;
• Ocular conditions as specified in the protocol;
• Subjects who desire monovision correction.
• Other protocol-defined exclusion criteria may apply.